MTX-COVAB is under clinical development by Memo Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MTX-COVAB’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTX-COVAB overview
MTX-COVAB is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other emergent COVID variants. The therapeutic candidates are being developed based on microfluidic technology platform DROPZYLLA. It targets spike protein of SARS-CoV-2. It is administered through inhalational and intravenous route.
Memo Therapeutics overview
Memo Therapeutics is a late-stage biotech company primarily focuses on the development of therapeutic antibodies. The company’s main product, AntiBKV, is a neutralizing antibody designed to treat BK virus infections in kidney transplant recipients. In addition to AntiBKV, MTx’s product pipeline includes therapeutic antibodies targeting infectious diseases such as cytomegalovirus (CMV), and undisclosed immuno-oncology targets. The company’s products are primarily used in the healthcare industry, specifically in the treatment of virus infections and cancer. MTx has a strategic partnership with Ono Pharmaceutical for the development of its products. The company’s unique nano droplet technology and immortal cell libraries allow it to identify and isolate potent antibodies at an unprecedented rate. Memo Therapeutics is headquartered in Schlieren, Zurich, Switzerland.
For a complete picture of MTX-COVAB’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
